Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06553027 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
A Phase 3 study of Parkinson Disease, sponsored by Cerevance.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT06553027 is a Phase 3 study of Parkinson Disease that is actively recruiting participants, run by Cerevance. The registered enrollment target is 330 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06553027, a Phase 3 study of Parkinson Disease, is actively recruiting participants, sponsored by Cerevance.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVN424 75 mg
- DRUG CVN424 150 mg
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- SFM Clinical Research, LLC - Boca Raton
- K2 Medical Research - Maitland
- Renstar Medical Research - Ocala
- N1 Research LLc - Orlando
- Parkinson's Disease Center of SWFL - Port Charlotte
- University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - Brain & Spine Institute - Port Orange
- USF Parkinson's Disease and Movement Disorders Center - Tampa
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
- St. Joseph's Hospital and Medical Center - Phoenix
California
- Parkinson's Research Centers of America - Orange county - Aliso Viejo
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Georgia
- Atlanta Neuroscience Institute - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06553027
The ClinicalTrials.gov registry entry for NCT06553027 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The listed sponsor is Cerevance, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06553027 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06553027 about?
NCT06553027 is a clinical study titled "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications". This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. ...
What is the current status of trial NCT06553027?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-09-20. Estimated completion is 2026-03.
What conditions does trial NCT06553027 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06553027?
The interventions under investigation include: Placebo (DRUG), CVN424 75 mg (DRUG), CVN424 150 mg (DRUG).
Who is sponsoring clinical trial NCT06553027?
This trial is sponsored by Cerevance, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06553027 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.